Salute e Benessere
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Now pet owners have a convenient, new management option to support the hearts of dogs with CHF: a liquid version of VETMEDIN , one of the leading canine cardiology medications in the world. Previous studies have shown that VETMEDIN could help increase the survival time and quality of life in dogs due to MMVD or DCM.
VETMEDIN® Solution (pimobendan oral solution) and VETMEDIN® (pimobendan) Chewable Tablets are for use in dogs with clinical evidence of heart failure only and should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information, see full prescribing information for Vetmedin Solution or see full prescribing information for Vetmedin Chewable Tablets or visit Vetmedinclinic.com
"We continue to deliver new innovations rooted in robust clinical evidence to help more pets," said Daniel Watkins, VP US Pet Business, Boehringer Ingelheim. "We know some dogs and pet owners may prefer a liquid medication, especially for smaller dogs. With VETMEDIN Solution, an easy-to- use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives."
VETMEDIN Solution, now available in the U.S., provides the same dual mode of action as VETMEDIN Chewable Tablets. The flavorless, twice-daily liquid oral solution should be administered directly into the dog's mouth.
Since VETMEDIN was first introduced 25 years ago, dogs and their owners around the world have enjoyed more than 1 million years of additional life to love. VETMEDIN Chewable Tablets are approved for the management of the signs of mild, moderate, or severe CHF in dogs due to clinical MMVD or DCM. VETMEDIN Chewable Tablets are indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
Boehringer Ingelheim also offers VETMEDIN -CA1 (pimobendan), which has FDA conditional approval for use in dogs with Stage B2 preclinical MMVD – which may enable a delay in the onset of heart failure symptoms.
For more information, visit www.boehringer-ingelheim.com/animal-health .
VETMEDIN Solution and VETMEDIN Chewable Tablets are for use in dogs with clinical evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN Solution and VETMEDIN Chewable Tablets should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information, see full prescribing information
or visit Vetmedinclinic.com
For more information, see full prescribing information or visit Vetmedinclinic.com
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Lean more at boehringer-ingelheim.com/us.
Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at boehringer-ingelheim.com/animal-health.
Chrissy Jones
Director, Corporate Affairs Boehringer Ingelheim
christine.jones@boehringer.com
References
Keene, Bruce W et al. "ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs." vol. 33,3 (2019): 1127-1140. doi:10.1111/jvim.15488
Häggström, J et al. "Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study." vol. 27,6 (2013): 1441-51. doi:10.1111/jvim.12181
Lombard, Christophe W et al. "Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs."
vol. 42,4 (2006): 249-61. doi:10.5326/0420249
Epidemiologic simulation of Vetmedin usage 1999-2024, based on EPIC 2016 JVIM (MMVD, stage B2), QUEST 2008 JVIM (MMVD, stage C), PROTECT 2012 JVIM (DCM, stage B2), O`Grady 2008 JVIM
(DCM, stage C), Fuentes 2002 JVIM (DCM stage C) and BI-owned sales data.
VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.
View original content: https://www.prnewswire.co.uk/news-releases/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs-302314392.html